Efficacy and safety of recombinant human interleukin-11 for the treatment of thrombocytopenia after chemotherapy: a Meta-analysis
10.13699/j.cnki.1001-6821.2017.18.024
- VernacularTitle:重组人白细胞介素-11治疗化疗后血小板减少症疗效与安全性
- Author:
Ying CHEN
1
;
Si-Yi LIU
;
Rong WANG
;
Fu-Ying LIU
;
Guo-Hua CHENG
Author Information
1. 暨南大学药学院
- Keywords:
chemotherapy;
recombinant human interleukin-11;
thrombocytopenia;
Meta-analysis
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(18):1817-1819,1846
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of recombinant human interleukin-11 (rhIL-11) in patients with thrombocytopernia after chemotherapy.Methods Using the method of evidence-based medicine,all the parallel controls of rhIL-11 combined with standard therapy and standard therapy computer-aided search of China National knowledge infrastructure (CNKI),VIP-Chinese science and technology periodical database,Wanfang data knowledge service platform,Cochrane Library,PubMed and Wed of Science.The Meta-analysis of the data was carried out by using RevMan 5.3 software.Results Totally 15 literatures were included in this series,with a total of 734 patients,including 370 cases in treatment group,other 364 cases in control group.The results of Meta-analysis showed that the platelet count in treatment group shorten the time interval of blood platelet ≤ 50 × 109/L duration (MD=-3.51,95％ CI:-4.66-2.36,Z=5.97,P＜0.01),shorten the duration of platelet recovery ≥ 100 × 109/L (MD =-3.20,95％ CI:-3.86-2.53,Z =9.38,P ＜ 0.01),proportion of platelet infusion(MD =-3.88,95％ CI:-6.15-1.61,Z =3.35,P ＜0.01) were better,and the proportion of adverse drug reaction of treatment group was lower than standard therapy (OR =0.17,95％ CI:0.09-0.32,Z =5.40,P ＜ 0.01).Conclusion RhIL-11 treatment of thrombocytopenia after chemotherapy is effective,significantly improve the patient's platelet count,shorten the duration and recovery time of thrombocytopenia,and better safety.
